Four numbers in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 22 other studies
the abstract, start to end
Ertugliflozin (RR=0.47, P=0.01) reduced the risk for retinal disease, while empagliflozin (RR=0.44, P=0.05) reduced the risk for …
SGLT-2i (RR=0.50, P=0.02), perhaps empagliflozin (RR=0.47, P=0.06), reduced the risk of …
← favours treatmentfavours comparator →
could be chanceNo interval given · direction only, strength unknown
Adverse events & safety
RR 0.47
Adverse events & safety
RR 0.44
Hypoglycaemia
RR 0.50
Hypoglycaemia
RR 0.47
SGLT2 inhibitorsOther glucose-loweringAdverse events & safetyHypoglycaemia
SGLT2 inhibitors × adverse events & safetyharms?mixed
unlikelylikely
0.00not counted
SGLT2 inhibitors × hypoglycaemiaharms?mixed
unlikelylikely
0.00not counted
← favours treatmentfavours comparator →
1 / 5